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Background: Acromegaly is a rare disease associated with an increased risk of developing cancer.
Case presentation: We report the case of a 72-year-old man who was diagnosed with acromegaly (IGF-1 770 ng/ml)
and breast cancer. Four years before he suffered from a colon-rectal cancer. Pituitary surgery and octreotide-LAR
treatment failed to control acromegaly. Normalization of IGF-1 (97 ng/ml) was obtained with pegvisomant therapy.
Four years after breast cancer surgery, 2 pulmonary metastases were detected at chest CT. The patient was started
on anastrozole, but, contrary to medical advice, he stopped pegvisomant treatment (IGF-I 453 ng/ml). Four months
later, chest CT revealed an increase in size of the metastatic lesion of the left lung. The patient was shifted from
anastrozole to tamoxifen and was restarted on pegvisomant, with normalization of serum IGF-1 levels (90 ng/ml).
Four months later, a reduction in size of the metastatic lesion of the left lung was detected by CT. Subsequent CT
scans throughout a 24-month follow-up showed a further reduction in size and then a stabilization of the metastasis.
Conclusions: This is the first report of a male patient with acromegaly and breast cancer. The clinical course of breast
cancer was closely related to the metabolic control of acromegaly. The rapid progression of metastatic lesion was
temporally related to stopping pegvisomant treatment and paralleled a rise in serum IGF-1 levels. Normalization of
IGF-1 after re-starting pegvisomant impressively reduced the progression of metastatic breast lesions. Control of
acromegaly is mandatory in acromegalic patients with cancer.
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Acromegaly is a chronic disease caused by excessive growth
hormone (GH) secretion by a GH-secreting pituitary
adenoma. Acromegalic patients suffer from high mor-
bidity and mortality mainly due to cardiovascular, metabolic
and respiratory diseases [1, 2]. The risk of developing ma-
lignancies is also increased in acromegalic patients [3].
However, cancer-related mortality is increased only in
acromegalic patients with poorly controlled disease, as
assessed by high circulating levels of Insulin-like-Growth-
Factor 1 (IGF-1) [4, 5]. Cancers of the thyroid, breast and
colon-rectum are the most commonly encountered* Correspondence: lchiovato@fsm.it
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unless otherwise stated.malignancies in patients with acromegaly [6–8]. Thus,
screening for tumors is recommended before, during and
after treatment for acromegaly [6]. Long term follow up is
also mandatory, mainly in patients who, despite treatment,
fail to achieve a good metabolic control, as assessed by
persistently elevated serum levels of IGF-1.
Male breast cancer is a rare malignancy that accounts
for 0.7 % of all breast cancers [9] and displays a signifi-
cant geographic variation in its incidence [10]. The mean
age at diagnosis is in the fifth decade [9] and the prog-
nosis is generally worse than in women [11]. Several fac-
tors including obesity, chronic liver disease, genetics,
and family history were reported to be implicated in the
development of the disease [12].
We hereby report the case of a patient who was diag-
nosed with acromegaly and breast cancer. Four years beforel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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To the best of our knowledge, this is the first report of a
male patient with acromegaly who developed breast can-
cer. In our opinion, relevant clinical and therapeutic infor-
mation can be drawn from the behavior of breast cancer
in relation to the metabolic control of acromegaly.
Case presentation
A 72-years-old male patient was referred to our Unit in
May 2007 for a non-toxic multinodular goiter, which
had recurred following a partial thyroidectomy per-
formed nearly 20 years before. The clinical history of the
patients revealed: 1) Type two diabetes mellitus, which
had been diagnosed at the age of 50 years and was
treated with insulin and oral glucose-lowering drugs; 2)
Hypertension since the age of 44 years, complicated by
retinopathy; 3) a previous (four years before) diagnosis
of colon-rectal adenocarcinoma (G2, without sub-serosal
infiltration), which had been treated with surgical resec-
tion (right colectomy with ileo-colic anastomosis) and
adjuvant chemotherapy. Resection margins were free of
disease and surrounding lymph nodes were not involved.Fig. 1 Serum levels of IGF-1 in relation to acromegaly control and breast c
IGF-I, 1. May 2007: Diagnosis of acromegaly (start of octreotide LAR treatme
Trans-sphenoidal adenomectomy, 4. June 2009: Octreotide LAR withdrawal
metastasis of breast cancer, 6. February 2011: Start anastrazol and spontane
tamoxifen, 8. July 2011: Re-start pegvisomant, 9. September 2011: ReductioIn the subsequent follow-up, no local relapse or meta-
static spread was detected.
When first seen in our clinic, broad hands and feet
were evident, which were reported to have increased in
size over the years. Physical examination also revealed
coarse facial features, enlargement of the nose, lips and
ears, pronounced jaw with attendant macroglossia and
teeth gapping, generalized thickening of the skin. Weight
was 78 kg and height 172 cm, for a BMI of 26.36 kg/m2.
Blood tests showed high levels of GH (85.9 ng/ml).
Serum IGF-1 was much higher (770 ng/ml) than the ex-
pected elderly normal range (87–177 ng/ml). The serum
levels of IGF-1 during the whole follow-up are illustrated
in Fig. 1. The remaining pituitary hormones were within
the normal range [Table 1] with the exception of a
slightly elevated serum prolactin (30.8 μUI/ml. A diag-
nosis of active acromegaly was made. Pituitary MRI
showed a macroadenoma (20 mm in maximum diam-
eter). The sella turcica floor was depressed and the pitu-
itary stalk was displaced. The patient refused surgery,
and therapy with octreotide LAR (30 mg every 28 days)
was started. Further diagnostic work-up revealed heartancer evolution. The dotted line represents the upper normal limit for
nt), 2. June 2007: Surgery for breast cancer, 3. February 2008:
, start pegvisomant, 5. December 2010- January 2011: Diagnosis of lung
ous pegvisomant withdrawal, 7. June 2011: Anastrazol withdrawal, start
n in diameter of pulmonary lesions
Table 1 Hormonal findings at diagnosis of acromegaly
Parameters Patient values Normal values
GH (ng/ml) 85.9 <=1
IGF-I (ng/ml) 770 87–177
Prolactin (mcUI/ml) 30.8 2.5–17
ACTH (pg/ml) 33.3 0–71
Cortisol (mcg/dl) 16.7 5–23.3
TSH (mIU/l) 0.857 0.4–4
FT4 (ng/dL) 0.91 0.8–1.9
FT3 (pg/mL) 2.46 1.8–4.2
Tg Ab (IU/ml) 12.6 <60
TPO Ab (IU/ml) 13.7 <60
FSH (mIU/ml) 7.94 0.7–11.1
LH (mIu/ml) 2.67 0.8–7.6
Testosterone (ng/dl) 246 181–758
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aortic valve with mild aortic insufficiency) and prostate
hypertrophy. Thyroid ultrasound confirmed a relapsing
multinodular goiter (estimated thyroid volume: 89 ml).
Fine needle aspiration cytology of the main thyroid nod-
ules was consistent with benign lesions. Physical examin-
ation also revealed a firm nodule of the left breast
(upper-outer quadrant) with palpable axillary nodes.
Cytological examination of the breast lesion was diag-
nostic for malignancy. In June 2007, the patient under-
went radical breast surgery. 12 lymph-nodes were
surgically removed from the axillary region. At histology
breast cancer was a hormone-sensitive (ER+ 70 %, PR+
20 %), in situ ductal breast carcinoma with micro-
infiltrating spots (<1 mm), (pT1mic, pN0M0 G2, Ki67
10 %, c-erb B2 DAKO HerceptTest 1+ neg). All exam-
ined lymph-nodes were free of metastatic involvement.
The contralateral breast was evaluated by physical exam-
ination and ultrasound. A synchronous breast cancer
was excluded. A detailed family history was also collected,
which was negative for the presence of either breast or
ovary cancer. The patient received post-surgical radiother-
apy (50 Gy in the left mammary region) with no adjuvant
systemic treatment.
In February 2008, ten months after starting octreotide
LAR, the serum levels of IGF-1 were still high (531 ng/ml)
and the patient accepted to undergo trans-sphenoid sur-
gery. Histological examination confirmed a somatothrope-
cell pituitary adenoma. Immediately after pituitary surgery
the IGF-1 serum levels decrease (192 ng/ml). Two months
later, the IGF-1 serum levels raised again (372 ng/ml),
which was consistent with the discovery of residual aden-
omatous tissue at pituitary MRI. Octreotide LAR treat-
ment was re-instituted. 17 months after surgery, due to
inadequate control of acromegaly on octreotide LAR(January 2009: GH= 7.5 ng/ml, IGF-1 = 292 ng/ml; July
2009: IGF-I = 231 ng/ml), pegvisomant (10 mg/day) treat-
ment was started. Two months later, normal levels of
serum IGF-I (97 ng/ml) were obtained.
In December 2010 a standard X-ray and a CT of the
chest showed a metastatic lesion located in the lower
lobe of the right lung, with a maximum diameter of
2.5 cm. A second metastatic lesion was evident in the
apical segment of the lower lobe of the left lung (max-
imum diameter = 1.5 cm) [Fig. 2: Panel a]. The patient
underwent right lower lobectomy. Histological examin-
ation confirmed the presence of a neoplastic nodule,
which was diagnosed as metastatic breast cancer (ER+,
Mammoglobin+). Hormone therapy with anastrozole
(1 mg/day) was started. Meanwhile, contrary to the med-
ical advice, the patient stopped pegvisomant treatment.
IGF-1 serum levels increased again (453 ng/ml). In June
2011, progression of the metastatic lesion in the lower
lobe of the left lung (from 1.5 cm to 2 cm maximum
diameter) was observed at chest CT [Fig. 2: Panel b].
Two months later, a widespread metastatic disease of
bone was detected at PET-FDG. Due to the neoplastic
progression, the patient was shifted from Anastrazol to
Tamoxifen (20 mg/day) treatment. In July 2011, the pa-
tient was re-started on pegvisomant treatment (10 mg/
day), which led to a normalization of serum IGF-1 levels
(90 ng/ml). A further chest CT was performed in
September 2011 and displayed a significant reduction
in size of the left lung metastasis (1.5 cm maximum
diameter) [Fig. 2: Panel c]. In April 2012 this lung me-
tastasis was found to be smaller than in the previous CT
(1.1 cm of maximum diameter). Subsequent CT scans,
performed 6, 12 and 20 months later [Fig. 2: Panel d],
showed no progression of the metastatic lung disease.
The patient remains in fair clinical conditions, has a
good control of acromegaly (January 2014: IGF-1 =
76 ng/ml) and his treatment still includes pegvisomant
for acromegaly and tamoxifen for metastatic breast
cancer.
Conclusions
We report the case of a caucasian male patient who ini-
tially suffered from colorectal cancer and subsequently
was diagnosed with acromegaly and breast cancer. Acro-
megaly was not cured by trans-sphenoidal surgery, was
partially resistant to octreotide LAR and was successfully
controlled by pegvisomant treatment, as assessed by
IGF-1 serum measurements. Clinically relevant changes
in the progression of breast cancer and metastatic lesions
were observed in relation to the metabolic control of acro-
megaly. A few peculiar aspects deserve discussion.
First, the patient was a man and, to the best of our
knowledge, there is no previous description of a male
patient with acromegaly and breast cancer. Even in the
Fig. 2 CT scan of the chest showing the radiological history of the metastatic lesion located in the apical segment of the lower lobe of the left
lung. Panel a (01/2011): first evidence (maximum diameter 1.5 cm). Panel b (5/2011): dimensional increase after pegvisomant withdrawal
(maximum diameter 2 cm). Panel c (09/2011): dimensional shrinkage after pegvisomant restart (maximum diameter 1.5 cm). Panel d (01/2014):
further dimensional shrinkage under pegvisomant treatment (maximum diameter 1.1 cm)
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the Authors did not report a case associated with acro-
megaly. Although a single observation does not allow es-
tablishing a causal link between the two pathologic
conditions, the fact that both acromegaly (40–90 cases/
million/year) and male breast cancer (10 cases/million/
year) are rare diseases argues against a chance associ-
ation. Although the mechanisms by which acromegaly
results in an increased risk of cancer have not been fully
clarified, in vitro studies demonstrated that GH and
IGF-1 have a proliferative and anti-apoptotic effect on
different cell lines, eventually leading to neoplastic evo-
lution [14]. Moreover, high serum levels of GH and IGF-
1 enhance the proliferation rate of epithelial cells of the
sigma crypts, which, by increasing the length of colon
and sigma, would predispose to the development of
colon-rectal cancer [15]. IGF-1, after binding to its re-
ceptor, is also known to increase the proliferation rate of
estrogen-dependent breast cancer cell lines. Based on
the above evidence, the co-existence of breast cancerand acromegaly might not be surprising. Given the long
history of acromegaly, it also conceivable to believe that
in our patient a cause effect relationship could exist be-
tween the endocrine disease and colon-rectal cancer. A
genetic background linking GH secreting pituitary aden-
omas, colon-rectal cancer and breast cancer might also
be hypothesized. In a study by Georgitsi et al., the Au-
thors evaluated the role of AIP mutations, which are
known to occur in pituitary adenomas, in the genesis of
common cancers (prostate, breast and colon-rectal can-
cer). However, no AIP mutation could be detected in
these types of cancer. To our knowledge, no other study
evaluated the existence of genetic link between acromeg-
aly, colon-rectal and breast cancer [16].
Second, the aggressive behavior of breast cancer was
unexpected in this patient, due to the favorable prognos-
tic TNM stage at diagnosis (pT1a mic, N0). Also intri-
guing is the observation that the metastatic progression
of breast cancer was temporally related to the interrup-
tion of pegvisomant treatment. Due to the lack of proper
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the association between acromegaly control and the on-
set of breast cancer metastasis. However, on the other
hand, the rapid spread of the metastatic lesions occurred
concomitantly to a rise in serum IGF-1 levels. The subse-
quent normalization of IGF-1, due to the re-introduction
of pegvisomant treatment, was followed by a reduction in
size and a stabilization of the lung metastasis. This se-
quence of events is in agreement with the observations of
Chae et al. [17], who reported an impressive amelioration
of metastatic breast cancer in a female patient with acro-
megaly being treated with octreotide LAR. At variance
with octreotide LAR, in vivo data on the anti-cancer ef-
fect of pegvisomant are scanty. Yin et al. demonstrated
that pegvisomant is more effective than octreotide LAR
in suppressing the GH-IGF-1 axis, thus implying that
this GH-receptor blocker drug could be effective in
treating several types of tumors, such as breast and colon-
rectal cancers [18].
The apparent failure of the elective treatment with
anastrozole and the favorable response to tamoxifen
could be explained by several factors. Previous studies
demonstrated that cross talks between the signaling
pathways of estrogen receptor (ER) and IGF-1 receptor
(R) play a crucial role in determining resistance to anti-
estrogen endocrine therapy in breast cancer [19–21]. In
vitro experiments by Lisztwan et al. demonstrated that
adding the aromatase blocker letrozole to an inhibitor of
the IGF-1 R pathway synergistically blocks the prolifera-
tion and induces apoptosis of breast cancer cells [22].
Taken together, these findings would suggest that a dual
targeting of IGF-1 R and ER pathways would prevent or
delay the onset of endocrine resistance. At variance with
this assumption, a randomized, open-label, phase III trial
reported similar event-free, recurrence-free, and overall
survival in 667 postmenopausal women with ER-positive
early-stage breast cancer who received treatment with
tamoxifen or tamoxifen + octreotide LAR as adjuvant
therapy [23]. However, these negative findings were ob-
tained in patients with normal GH and IGF-1, a completely
different clinical situation from that of our acromegalic
patient who, due to the high levels of circulating IGF-1,
had a strong activation of the IGF-1-R pathway. In turn,
this IGF-1 R activation could explain the apparent resist-
ance to anastrozole and the benefits observed with tam-
oxifen. Indeed, anastrozole was administered when the
circulating levels of IGF-1 were high due to the interrup-
tion of pegvisomant treatment, while the shift to tamoxi-
fen coincided with re-starting pegvisomant and the
subsequent metabolic control of acromegaly. Moreover,
tamoxifen itself might have been responsible for a further
reduction of IGF-1 serum levels. This IGF-1 lowering ef-
fect of tamoxifen was previously described both in acro-
megalic patients and in healthy subjects [24–27].In conclusion, we report for the first time the case of a
male acromegalic patient with breast cancer. The clinical
evolution of breast cancer in our patient highlights the
concept that the control of acromegaly might play a role
in the outcome of the coexistent neoplasia. No matter
how the control of acromegaly is achieved, suppression
of IGF-1 should be mandatory in acromegalic patients
with cancer.
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